As part of our Women in Pharma series, where we talk to leading figures in the life sciences, we hear from Şeyda Atadan Memiş, recently appointed general manager for Takeda UK and
Lung, breast, and non-prostate genitourinary (NGU) cancer treatments were the most exciting tracks due to the march towards personalised medicine and expanded immunotherapy options.
In response to the recent Association of British Pharmaceutical Industry (ABPI) report, which showed a sharp decline (41%) in clinical trials initiated by the UK in the period 2017 to 2021,
It's all change at Alphabet's life sciences business Verily, with a $1 billion funding round and a shake-up of its senior leadership, including a new chief executive and executive chairman,